Results 231 to 240 of about 700,247 (353)

Neonatal pulmonary hypertension in the NICU: a 10-year single-center experience. [PDF]

BMC Pediatr
Ay O, Gunes S, Erfidan E, Simsek A.
europepmc   +1 more source

Clinical Outcomes Post‐Transcatheter Aortic Valve Replacement in Patients With Hypertrophic Obstructive Cardiomyopathy

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Patients with hypertrophic obstructive cardiomyopathy (HOCM) were excluded from all major trials for transcatheter aortic valve replacement (TAVR). “Suicide left ventricle” occurring after TAVR is postulated to occur as a result of chronic pressure overload from fixed obstruction that is acutely relieved after the valve deployment ...
Muhammad Usman Almani, Vibhor Ahluwalia, Muhammad Yousuf, Jafar Alzubi, Mohammad Hamza, Raphael Bonita, Christian Witzke   +6 more
wiley   +1 more source

Right Ventricular Dysfunction in Lung Disease/Hypoxia-Associated Pulmonary Hypertension. [PDF]

J Am Heart Assoc
Shima H, Tsujino I, Nakaya T, Nakamura J, Igarashi-Sugimoto A, Sato T, Watanabe T, Ohira H, Hisada R, Kato M, Tsuneta S, Yokota I, Konno S.   +12 more
europepmc   +1 more source

Primary Pulmonary Hypertension in a Child

, 1969
B. N. SATYANARAYANA RAO, James H. Moller, Jesse E. Edwards   +2 more
openalex   +1 more source

A promise to save 100,000 trauma patients.

, 2013
Horton, Richard, Krug, Etienne, Mersch, Jeannot, Piot, Peter, Roberts, Ian, Shakur, Haleema   +5 more
core   +1 more source

Development of Keap1‐Nrf2 Protein–Protein Interaction Inhibitor Activating Intracellular Nrf2 Based on the Naphthalene‐2‐acetamide Scaffold, and its Anti‐Inflammatory Effects

ChemMedChem, EarlyView.
Pyrrolidine‐type naphthalene‐2‐acetamide compound 5i inhibits Kelch‐like ECH‐associated protein 1 (Keap1)‐nuclear factor erythroid 2‐related factor 2 (Nrf2) protein–protein interaction by binding to the Keap1‐DC domain; it subsequently activates intracellular Nrf2 and induces Nrf2‐target genes.
Daisuke Yasuda, Kai Toyoshima, Koujin Kojima, Hanako Ishida, Kazuma Kaitoh, Riyo Imamura, Kayoko Kanamitsu, Hirotatsu Kojima, Megumi Funakoshi‐Tago, Masanori Osawa, Tomoyuki Ohe, Tomoya Hirano   +11 more
wiley   +1 more source

Pulmonary Hypertension after Pregnancy [PDF]

, 1963
K. D. Bagshawe
openalex   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R. Srinivas, Randall Kaye   +7 more
wiley   +1 more source

Respiratory and Cardiovascular Function in Patients with Severe Pulmonary Hypertension

, 1964
Hans U. Wessel, Paul Kezdi, David W. Cugell   +2 more
openalex   +1 more source

Risk of Infections with SGLT2 Inhibitors Versus DPP4 Inhibitors: A Population‐Based Cohort Study Using Antibiotic Dispensing Data

Clinical Pharmacology &Therapeutics, EarlyView.
This study compared the number and cumulative dose of antibiotic dispensings among new users of sodium–glucose cotransporter‐2 (SGLT2) inhibitors and dipeptidyl peptidase‐4 (DPP4) inhibitors following hospital discharge in individuals with type 2 diabetes.
Maria J. Alfonso Arvez, George S. Q. Tan, Sam Wade, Zanfina Ademi, Jenni Ilomäki, J. Simon Bell   +5 more
wiley   +1 more source